ERBB2 and breast carcinoma: Neratinib, a TKI approved in 2017 for treatment of HER2+ breast cancer, was not associated with grade 3/4 cardiotoxicity for patients in a phase 2 trial, and little variation in LVEF versus baseline was noted across patients regardless of prior trastuzumab treatment [49].